Title: 2025-2026 Regular Session HR 304 PN 2263 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN2263
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session HR 304 PN 2263 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 2263 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.304 Session of 2025 INTRODUCED BY McNEILL, VENKAT, VITALI, SANCHEZ, HOHENSTEIN, DIAMOND, GIRAL, BERNSTINE, WAXMAN, BRENNAN, GUENST, MERSKI, CEPEDA-FREYTIZ AND HANBIDGE, SEPTEMBER 3, 2025 REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 4, 2025 A RESOLUTIONDesignating the month of September 2025 as "Prostate Cancer Awareness Month" in Pennsylvania.WHEREAS, The prostate is a small gland found only in men and located below the bladder; andWHEREAS, In some cases, prostate cancer can make the prostate enlarged; andWHEREAS, Prostate Cancer Research, a nonprofit organization under the National Cancer Research Institute, reports that the risk of prostate cancer increases with age with most cases diagnosed in men over 50 years of age; andWHEREAS, According to the Prostate Conditions Education Council, 1 in 8 American men will get prostate cancer and 1 in 41 men will die from prostate cancer; andWHEREAS, The American Cancer Society estimates that more than 13,000 new cases of prostate cancer will be diagnosed in 2025 in Pennsylvania; andWHEREAS, The American Cancer Society estimates that 1,500 1234567891011121314151617 Pennsylvanians will die of prostate cancer in 2025; andWHEREAS, The Centers for Disease Control and Prevention describes symptoms of prostate cancer that include difficulty starting urination, weak or interrupted flow of urine, trouble emptying the bladder completely, pain or burning during urination, blood in the urine and pain in the back, hips or pelvis; andWHEREAS, Prostate cancer can be dormant in a person's body for up to 20 years without symptoms, increasing the chance that a person may be sick without the person's knowledge; andWHEREAS, The American Cancer Society recommends that men with an average risk of prostate cancer start screening for prostate cancer at 50 years of age; andWHEREAS, For men at a high risk of developing prostate cancer and men who have a first-degree relative diagnosed with prostate cancer at an early age, screening should begin at 45 years of age; andWHEREAS, For men at even greater risk, including those with more than one first-degree relative who had prostate cancer at an early age, screening should begin at 40 years of age; andWHEREAS, Men should consult with their physician about the benefits of screening for prostate cancer; andWHEREAS, There are two tests used by physicians to screen for prostate cancer: a prostate-specific antigen test, which measures the level of prostate-specific antigen in the blood, and a digital rectal examination, which detects abnormalities of the prostate; andWHEREAS, If abnormalities are noted from either screening, a biopsy may be recommended to assist in diagnosing potential prostate cancer; therefore be it20250HR0304PN2263 - 2 - 123456789101112131415161718192021222324252627282930 RESOLVED, That the House of Representatives designate the month of September 2025 as "Prostate Cancer Awareness Month" in Pennsylvania.20250HR0304PN2263 - 3 - 123


================================================================================

Raw Text:
2025-2026 Regular Session HR 304 PN 2263 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 2263 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.304 Session of 2025 INTRODUCED BY McNEILL, VENKAT, VITALI, SANCHEZ, HOHENSTEIN, DIAMOND, GIRAL, BERNSTINE, WAXMAN, BRENNAN, GUENST, MERSKI, CEPEDA-FREYTIZ AND HANBIDGE, SEPTEMBER 3, 2025 REFERRED TO COMMITTEE ON HEALTH, SEPTEMBER 4, 2025 A RESOLUTIONDesignating the month of September 2025 as "Prostate Cancer Awareness Month" in Pennsylvania.WHEREAS, The prostate is a small gland found only in men and located below the bladder; andWHEREAS, In some cases, prostate cancer can make the prostate enlarged; andWHEREAS, Prostate Cancer Research, a nonprofit organization under the National Cancer Research Institute, reports that the risk of prostate cancer increases with age with most cases diagnosed in men over 50 years of age; andWHEREAS, According to the Prostate Conditions Education Council, 1 in 8 American men will get prostate cancer and 1 in 41 men will die from prostate cancer; andWHEREAS, The American Cancer Society estimates that more than 13,000 new cases of prostate cancer will be diagnosed in 2025 in Pennsylvania; andWHEREAS, The American Cancer Society estimates that 1,500 1234567891011121314151617 Pennsylvanians will die of prostate cancer in 2025; andWHEREAS, The Centers for Disease Control and Prevention describes symptoms of prostate cancer that include difficulty starting urination, weak or interrupted flow of urine, trouble emptying the bladder completely, pain or burning during urination, blood in the urine and pain in the back, hips or pelvis; andWHEREAS, Prostate cancer can be dormant in a person's body for up to 20 years without symptoms, increasing the chance that a person may be sick without the person's knowledge; andWHEREAS, The American Cancer Society recommends that men with an average risk of prostate cancer start screening for prostate cancer at 50 years of age; andWHEREAS, For men at a high risk of developing prostate cancer and men who have a first-degree relative diagnosed with prostate cancer at an early age, screening should begin at 45 years of age; andWHEREAS, For men at even greater risk, including those with more than one first-degree relative who had prostate cancer at an early age, screening should begin at 40 years of age; andWHEREAS, Men should consult with their physician about the benefits of screening for prostate cancer; andWHEREAS, There are two tests used by physicians to screen for prostate cancer: a prostate-specific antigen test, which measures the level of prostate-specific antigen in the blood, and a digital rectal examination, which detects abnormalities of the prostate; andWHEREAS, If abnormalities are noted from either screening, a biopsy may be recommended to assist in diagnosing potential prostate cancer; therefore be it20250HR0304PN2263 - 2 - 123456789101112131415161718192021222324252627282930 RESOLVED, That the House of Representatives designate the month of September 2025 as "Prostate Cancer Awareness Month" in Pennsylvania.20250HR0304PN2263 - 3 - 123